Uncategorized
University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy
CHICAGO--(BUSINESS WIRE)--University Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy (GA). GA is a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide (source 1,2). Within the past 3 years, University Retina has built their clinical trials p